Cargando…

PRLHR Immune Genes Associated With Tumor Mutation Burden can be Used as Prognostic Markers in Patients With Gliomas

Tumor mutation burden (TMB) is a useful biomarker for predicting the prognosis and efficacy of immune checkpoint inhibitor (ICIs). In this study, we aimed to explore the prognostic value of TMB and TMB-related PRLHR immune genes as prognostic markers in patients with gliomas. We downloaded MAF files...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yi, Xiang, Juan, Peng, Gang, Shen, Chenfu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9253814/ https://www.ncbi.nlm.nih.gov/pubmed/35800054 http://dx.doi.org/10.3389/fonc.2022.620190

Ejemplares similares

Development and Validation of a Tumor Mutation Burden–Related Immune Prognostic Model for Lower-Grade Glioma
por: Yin, Wen, et al.
Publicado: (2020)

Identification of tryptophan metabolic gene-related subtypes, development of prognostic models, and characterization of tumor microenvironment infiltration in gliomas
por: Liu, Yi, et al.
Publicado: (2022)

Polymorphisms of PRLHR and HSPA12A and risk of gastric and colorectal cancer in the Chinese Han population
por: Su, Qinghua, et al.
Publicado: (2015)

Omics- and Pharmacogenomic Evidence for the Prognostic, Regulatory, and Immune-Related Roles of PBK in a Pan-Cancer Cohort
por: Liu, Yi, et al.
Publicado: (2021)

Significance of Tumor Mutation Burden in Immune Infiltration and Prognosis in Cutaneous Melanoma
por: Kang, Kai, et al.
Publicado: (2020)

Prognostic Role of Tumor Mutation Burden Combined With Immune Infiltrates in Skin Cutaneous Melanoma Based on Multi-Omics Analysis
por: Yan, Junya, et al.
Publicado: (2020)

FCGBP Is a Prognostic Biomarker and Associated With Immune Infiltration in Glioma
por: Yan, Tengfeng, et al.
Publicado: (2022)

Correlation of tumor mutational burden with prognosis and immune infiltration in lung adenocarcinoma
por: Li, Lin, et al.
Publicado: (2023)

Prognostic Role of Tumor Mutational Burden in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Huang, Taobi, et al.
Publicado: (2021)

Identification of the novel prognostic biomarker, MLLT11, reveals its relationship with immune checkpoint markers in glioma
por: Chen, Long, et al.
Publicado: (2022)

Prognostic value of tumor mutation burden in patients with advanced gastric cancer receiving first-line chemotherapy
por: Duan, Xiao-Peng, et al.
Publicado: (2023)

MYD88 Is a Potential Prognostic Gene and Immune Signature of Tumor Microenvironment for Gliomas
por: Guo, Qinglong, et al.
Publicado: (2021)

CASP4 can be a diagnostic biomarker and correlated with immune infiltrates in gliomas
por: Tian, Guopeng, et al.
Publicado: (2023)

RNA Sequencing Data for FFPE Tumor Blocks Can Be Used for Robust Estimation of Tumor Mutation Burden in Individual Biosamples
por: Sorokin, Maxim, et al.
Publicado: (2021)

Concurrent predictors of an immune responsive tumor microenvironment within tumor mutational burden-high breast cancer
por: Sammons, Sarah, et al.
Publicado: (2023)

Association of MSH2 Expression With Tumor Mutational Burden and the Immune Microenvironment in Lung Adenocarcinoma
por: Jia, Mingming, et al.
Publicado: (2020)

Prognostic analysis of patients with breast cancer based on tumor mutational burden and DNA damage repair genes
por: Teng, Xu, et al.
Publicado: (2023)

Expression and Prognostic Value of ARID5A and its Correlation With Tumor-Infiltrating Immune Cells in Glioma
por: Zhou, Quan, et al.
Publicado: (2021)

DNA methylation-based patterns for early diagnostic prediction and prognostic evaluation in colorectal cancer patients with high tumor mutation burden
por: Huang, Hao, et al.
Publicado: (2023)

KDELR1 Is an Independent Prognostic Predictor and Correlates With Immunity in Glioma
por: Yuan, Yifan, et al.
Publicado: (2022)

The Clinical Implications of Tumor Mutational Burden in Osteosarcoma
por: Xie, Lu, et al.
Publicado: (2021)

Identification and Verification on Prognostic Index of Lower-Grade Glioma Immune-Related LncRNAs
por: Wen, Jing, et al.
Publicado: (2020)

Beyond Tumor Mutation Burden: Tumor Neoantigen Burden as a Biomarker for Immunotherapy and Other Types of Therapy
por: Wang, Peipei, et al.
Publicado: (2021)

EDEM2 is a diagnostic and prognostic biomarker and associated with immune infiltration in glioma: A comprehensive analysis
por: Wu, Yuxi, et al.
Publicado: (2023)

LCTL Is a Prognostic Biomarker and Correlates With Stromal and Immune Infiltration in Gliomas
por: Su, Jun, et al.
Publicado: (2019)

Glioma-Associated Stromal Cells Stimulate Glioma Malignancy by Regulating the Tumor Immune Microenvironment
por: Cai, Xiangming, et al.
Publicado: (2021)

Discussion of tumor mutation burden as an indicator to predict efficacy of immune checkpoint inhibitors: A case report
por: Wu, Mingrui, et al.
Publicado: (2022)

Tumor Mutation Burden, Expressed Neoantigens and the Immune Microenvironment in Diffuse Gliomas
por: Yu, Guangyang, et al.
Publicado: (2021)

Development and Validation of an IDH1-Associated Immune Prognostic Signature for Diffuse Lower-Grade Glioma
por: Deng, Xiangyang, et al.
Publicado: (2019)

Combinations of Single-Gene Biomarkers Can Precisely Stratify 1,028 Adult Gliomas for Prognostication
por: Chan, Aden Ka-Yin, et al.
Publicado: (2022)

MicroRNA-25 promotes cell proliferation, migration and invasion in glioma by directly targeting cell adhesion molecule 2
por: Peng, Gang, et al.
Publicado: (2022)

Prognostic value of lactate metabolism-related gene expression signature in adult primary gliomas and its impact on the tumor immune microenvironment
por: Wang, Zhihao, et al.
Publicado: (2022)

Tumor Mutational Burden Associated With Response to Hyperthermic Intraperitoneal Chemotherapy
por: Zeng, Lisi, et al.
Publicado: (2022)

Characteristics of Pan-Cancer Patients With Ultrahigh Tumor Mutation Burden
por: Yuan, Hong, et al.
Publicado: (2021)

FAT3 Mutation Is Associated With Tumor Mutation Burden and Poor Prognosis in Esophageal Cancer
por: Guo, Zixin, et al.
Publicado: (2021)

Characterization of Frequently Mutated Cancer Genes and Tumor Mutation Burden in Chinese Breast Cancer
por: Xiao, Weikai, et al.
Publicado: (2021)

Molecular Pathological Markers Correlated With the Recurrence Patterns of Glioma
por: Ge, Shunnan, et al.
Publicado: (2021)

The pro-invasive factor COL6A2 serves as a novel prognostic marker of glioma
por: Zhu, Jinchao, et al.
Publicado: (2022)

The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis
por: Wu, Yongfeng, et al.
Publicado: (2019)

Prognostic and Treatment Guiding Significance of MRI-Based Tumor Burden Features and Nodal Necrosis in Nasopharyngeal Carcinoma
por: Chen, Xi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jbfv8oqhjgodjv66k7mqpqp486